Associated Genetic Biomarkers
BRAF Y472C is present in 0.00% of AACR GENIE cases, with uterine corpus neoplasm having the greatest prevalence .
BRAF Y472C is a predictive biomarker for use of dasatinib in patients.
Non-small cell lung carcinoma has the most therapies targeted against BRAF Y472C or its related pathways .
Non-Small Cell Lung Carcinoma -
BRAF Y472C serves as an inclusion eligibility criterion in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial that contains BRAF Y472C as an inclusion criterion, 1 is phase 1 (0 open).
Trials with BRAF Y472C in the inclusion eligibility criteria most commonly target malignant solid tumor and non-small cell lung carcinoma .
Significance of BRAF Y472C in Diseases
Non-Small Cell Lung Carcinoma +
BRAF is mutated in 5.34% of non-small cell lung carcinoma patients .
BRAF Y472C is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains BRAF Y472C and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) .
Dasatinib is currently approved for use in patients with BRAF Y472C in non-small cell lung carcinoma .
Malignant Solid Tumor +
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.